Home / Biopharma / Valeant Pharmaceuticals International (NYSE:VRX) Receives A Joint Takeover Offer TPG Capital Management

Valeant Pharmaceuticals International (NYSE:VRX) Receives A Joint Takeover Offer TPG Capital Management

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) [Trend Analysis] has kept up with the changing appetite, stock decreased around -0.66% in early session as it gain volume of 13.89 Million shares, then traded at $26.94. ¬†Valeant Pharmaceuticals International Inc (VRX) declared that it received a joint takeover offer from Japan’s Takeda Pharmaceutical Co Ltd and TPG Capital Management LP this spring that Canadian drugmaker discarded, according to WSJ, quoting people familiar with the matter.

Valeant discarded offer, which came a month or two ago, before the company hired its new chief executive, Joseph Papa, in April, and did not include a firm price, the newspaper reported. The newspaper also said there are currently no talks between the three companies following the bid’s rejection, and that Valeant’s board was seeking to give Papa time to chart a course for the company.

Moving toward the volatility measures, the price volatility of stock was 5.53% for a week and 9.14% for a month as well as price volatility’s Average True Range for 14 days was 2.29. The beta, which indicates risk in relegation to the market, remained 0.26. The firm past twelve months price to sales ratio was 0.90 and price to cash ratio remained 15.71. As far as the returns are concern, the return on equity was recorded as -4.60% and return on investment was 3.70%, while its return on asset stayed at -0.60%.

Noting a main crunch of analyst research by WSJ, VRX under observation of quarterly per share earnings, it has second quarter 2016 trend of $1.37, while in next quarter estimated EPS trend is $2.08 and for annual basis for 2016 estimated EPS is $8.48.

Relatively pool of WSJ analyst issues diverse rating, as for current level it has 6 experts rated as “BUY” security, 1 analyst recommend as “Overweight,” and 10 experts rated as “Hold”.

The liquidity measure in recent quarter results of company was recorded 1.00 as current ratio, on the other side the debt to equity ratio was 5.26. The Company has gross margin of 75.30% and profit margin was negative -2.80% in trailing twelve months.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) is ahead its 52 week low with 14.39%and going down from its 52 week high price with -89.79%. The company’s shares performance for the last one month was -22.85% and 2.59% in the previous week. The stock price of firm is moving down from its 20 days moving average with -8.14% and remote isolated negatively from 50 days moving average with -12.34%.


About Devon Leftovich

Check Also

Stocks Faring Away From Broker’s Choice: Opko Health (NASDAQ:OPK), Shire plc (NASDAQ:SHPG)

Several matter pinch shares of Opko Health, Inc. (NASDAQ:OPK) [Trend Analysis], as shares plunging -2.56% …

Leave a Reply

Your email address will not be published. Required fields are marked *